50899-03-1

Basic information

• Product Name: 4-Ethylsulfonylbenzaldehyde
• Synonyms: 4-Ethylsulfonylbenzaldehyde
• CAS NO: 50899-03-1
• Molecular Formula: C₉H₁₀O₃S
• Molecular Weight: 198.2389
• Mol File: 50899-03-1.mol

Chemical Properties

• Melting Point: 108～110℃
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Ethylsulfonylbenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Ethylsulfonylbenzaldehyde(50899-03-1)
• EPA Substance Registry System: 4-Ethylsulfonylbenzaldehyde(50899-03-1)

Safety Data

• Hazardous Substances Data: 50899-03-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-Ethylsulfonylbenzaldehyde is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional groups contribute to the development of new and effective compounds for these industries.
Used in Dye and Fragrance Production:
Due to its aromatic properties, 4-Ethylsulfonylbenzaldehyde is employed in the production of dyes and fragrances. Its chemical structure allows for the creation of a wide range of colors and scents, enhancing the quality and variety of products in these markets.
Used in Research and Development:
4-Ethylsulfonylbenzaldehyde serves as a versatile reagent in research and development. Its ability to participate in various chemical reactions makes it an essential tool for scientists working on new chemical processes and discoveries.

Upstream product

• 84211-94-9 4-(ethylthio)benzaldehyde 
• 108129-95-9 4-ethanesulfonyl-benzoyl chloride 
• 100613-79-4 1-ethanesulfonyl-4-diacetoxymethyl-benzene 
• 90561-19-6 1-(bromomethyl)-4-(ethylsulfonyl)benzene 
• 7569-34-8 ethyl p-tolyl sulfone 
• 459-57-4 4-fluorobenzaldehyde 
• 20035-08-9 sodium ethanesulfinate 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 

Downstream Products

• 101655-00-9 1-(4-ethanesulfonyl-benzylidenamino)-imidazolidine-2,4-dione 
• 106883-09-4 isonicotinic acid-(4-ethanesulfonyl-benzylidenehydrazide) 
• 102023-26-7 quinoline-2-carboxylic acid-(4-ethanesulfonyl-benzylidenehydrazide) 
• 107772-89-4 4-ethanesulfonyl-benzaldehyde-(4-isobutyl thiosemicarbazone) 
• 121-55-1 4-ethanesulfonyl-benzaldehyde-thiosemicarbazone 
• 100115-29-5 1-(4-ethanesulfonyl-benzylidenamino)-2-thioxo-imidazolidin-4-one 
• 87719-32-2 Etarotene 
• 84264-82-4 ethyl p-<(Z)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl>phenyl sulfone 
• 1026434-15-0 [1-(4-Ethanesulfonyl-phenyl)-meth-(E)-ylidene]-(4-methanesulfonyl-phenyl)-amine 
• 84264-87-9 ethyl p-[2-(1,1,3,3-tetramethyl-5-indanyl)propenyl]phenylsulphone 
• 84264-83-5 ethyl p-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]phenylsulphone 
• 917396-45-3 (4-(ethylsulfonyl)phenyl)methanol 
• 90561-19-6 1-(bromomethyl)-4-(ethylsulfonyl)benzene 

Relevant articles and documents

Sulfonylation of Aryl Halides by Visible Light/Copper Catalysis

An efficient visible-light-assisted, copper-catalyzed sulfonylation of aryl halides with sulfinates is reported. In our protocol, a single ligand CuI photocatalyst formed in situ was used in the photocatalytic transformation. Diverse organosulfones were obtained in moderate to good yields. This strategy demonstrates a promising approach toward the synthesis of diverse and useful organosulfones.

Synthesis method of beta-benzoamino acid compound

The invention relates to a preparation method of a beta-benzoamino acid compound. The preparation method comprises the following steps: (1) acquiring a racemate compound shown as formula (I); (2) reacting the racemate compound shown as the formula (I) wit

1,2,3-BENZOTRIAZOLE DERIVATIVES AS ROR GAMMA T MODULATORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, G, L, R1, Rx, Ry, X1, X2, X3, X4, n, p, q and t are

MODULATORS OF ROR-GAMMA

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ROR-GAMMA

Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions co

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co

COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY

Compounds of formula (I): wherein X, L1, R1, L2, R2, R3, and R4 are as defined herein, are useful in the treatment or prophylaxis of Duchenne muscular dystrophy, Becker muscular dystrophy, or cachexia.

Tetrahydronaphthalene and indane compounds useful as anti-tumor agents

This invention is directed to tetrahydronaphthalene and indane compounds and processes thereto. These compounds are useful as tumor inhibiting agents, in the treatment of neoplasms and dermatological conditions.